Treatment of dementia with Lewy bodies and Parkinson's disease dementia
Identifieur interne : 001799 ( Istex/Corpus ); précédent : 001798; suivant : 001800Treatment of dementia with Lewy bodies and Parkinson's disease dementia
Auteurs : Werner PoeweSource :
- Movement Disorders [ 0885-3185 ] ; 2005-08.
English descriptors
- KwdEn :
Abstract
Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20544
Links to Exploration step
ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20544</idno><idno type="url">https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001799</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08">2005-08</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S12</biblScope><biblScope unit="supplement">S12</biblScope><biblScope unit="page" from="S77">S77</biblScope><biblScope unit="page" to="S82">S82</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno><idno type="DOI">10.1002/mds.20544</idno><idno type="ArticleID">MDS20544</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>DLB</term><term>PDD</term><term>antipsychotics</term><term>cholinesterase inhibitor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Medical University of Innsbruck, Austria</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>DLB</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PDD</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cholinesterase inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>antipsychotics</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>6.015</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1176</abstractCharCount><pdfWordCount>4059</pdfWordCount><pdfCharCount>26859</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>163</abstractWordCount></qualityIndicators><title>Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><genre><json:string>Serial article</json:string></genre><host><volume>20</volume><pages><total>6</total><last>S82</last><first>S77</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S12</issue><author><json:item><name>Werner Poewe MD</name></json:item><json:item><name>Gregor Wenning MD, PhD</name></json:item></author><subject><json:item><value>Research Review</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20544</json:string></doi><id>C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2005</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><author><persName><forename type="first">Werner</forename><surname>Poewe</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A‐6020 Innsbruck, Austria</p></note><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-08"></date><biblScope unit="vol">20</biblScope><biblScope unit="issue">S12</biblScope><biblScope unit="supplement">S12</biblScope><biblScope unit="page" from="S77">S77</biblScope><biblScope unit="page" to="S82">S82</biblScope></imprint></monogr><idno type="istex">C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</idno><idno type="DOI">10.1002/mds.20544</idno><idno type="ArticleID">MDS20544</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>DLB</term></item><item><term>PDD</term></item><item><term>cholinesterase inhibitor</term></item><item><term>antipsychotics</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2005-08">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C9B9F098E1D58A1ADC905DC9169EF4CF501D3082/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="85"><doi origin="wiley" registered="yes">10.1002/mds.v20:12+</doi><titleGroup><title type="supplementTitle">Atypical parkinsonian disorders</title></titleGroup><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">S12</numbering><numbering type="supplement" number="S12">S12</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Gregor</givenNames><familyName>Wenning</familyName><degrees>MD, PhD</degrees></personName></creator></creators><coverDate startDate="2005-08">August 2005</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20544</doi><idGroup><id type="unit" value="MDS20544"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Review</title><title type="tocHeading1">Research Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2005-08-09"></event><event type="publishedOnlineFinalForm" date="2005-08-09"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S77</numbering><numbering type="pageLast">S82</numbering></numberingGroup><correspondenceTo>Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A‐6020 Innsbruck, Austria</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20544.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="58"></count><count type="wordTotal" number="4508"></count></countGroup><titleGroup><title type="main" xml:lang="en">Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title><title type="short" xml:lang="en">Treatment of DLB and PD Dementia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName><contactDetails><email>werner.poewe@uibk.ac.at</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, Medical University of Innsbruck, Austria</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">DLB</keyword><keyword xml:id="kwd2">PDD</keyword><keyword xml:id="kwd3">cholinesterase inhibitor</keyword><keyword xml:id="kwd4">antipsychotics</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of DLB and PD Dementia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Treatment of dementia with Lewy bodies and Parkinson's disease dementia</title></titleInfo><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Medical University of Innsbruck, Austria</affiliation><description>Correspondence: Department of Neurology, Medical University of Innsbruck, Anichstrasse 35, A‐6020 Innsbruck, Austria</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-08</dateIssued><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">58</extent><extent unit="words">4508</extent></physicalDescription><abstract lang="en">Cognitive decline and dementia affect approximately 30% to 40% of patients with idiopathic Parkinson's disease during the course of their illness. PD‐dementia (PDD) and dementia with Lewy bodies (DLB) are second to Alzheimer's disease in causing degenerative dementia in the elderly. The nosological distinction of the conditions has remained controversial because of broad clinical and pathological overlap. Treatment issues in both clinical settings are virtually identical. Treatment of Parkinsonism is often complicated by drug‐induced psychosis and reduced levodopa responsiveness. Cognition, alertness, attention, as well as apathy or aggressive behavior have been shown to respond to treatment with cholinesterase inhibitors in randomized controlled trials both in DLB and PDD. Such treatment may also improve hallucinosis, but many patients will require add‐on treatment with atypical neuroleptics to control drug‐induced psychotic reactions. Clozapine and quetiapine are the drugs most commonly used and, contrary to classic neuroleptics, risperidone or olanzapine do not seem to cause severe side effects according to published data. © 2005 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>DLB</topic><topic>PDD</topic><topic>cholinesterase inhibitor</topic><topic>antipsychotics</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Gregor</namePart><namePart type="family">Wenning</namePart><namePart type="termsOfAddress">MD, PhD</namePart></name><subject><genre>article category</genre><topic>Research Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>S12</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>S12</number></detail><extent unit="pages"><start>S77</start><end>S82</end><total>6</total></extent></part></relatedItem><identifier type="istex">C9B9F098E1D58A1ADC905DC9169EF4CF501D3082</identifier><identifier type="DOI">10.1002/mds.20544</identifier><identifier type="ArticleID">MDS20544</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001799 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001799 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C9B9F098E1D58A1ADC905DC9169EF4CF501D3082
|texte= Treatment of dementia with Lewy bodies and Parkinson's disease dementia
}}
| This area was generated with Dilib version V0.6.23. |  |